Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...

– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the ...

In 1981, physicians in Los Angeles reported five young patients with Pneumocystis pneumonia, a rare lung infection later recognized as the first sign of HIV infection and a defining illness of AIDS.

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

Gilead Sciences (GILD) announced on Thursday that its Phase 3 ARTISTRY-1 trial, which tested its new single-tablet regimen of bictegravir and lenacapavir in adults with HIV, reached the primary ...

A new single-pill HIV treatment has proved as effective as regimens of up to 11 tablets a day in suppressing the virus in hard-to-treat patients. It’s “a potential breakthrough for a growing cohort of ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented ...